P/E ratio for Lexicon Pharmaceuticals (LXRX)

P/E ratio history for Lexicon Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Eterna Therapeutics ERNA	-0.0502	-95.65%	🇺🇸 USA
Regeneron Pharmaceuticals REGN	19.2	-1,762.14%	🇺🇸 USA
Ultragenyx RARE	-4.28	270.78%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	86.1	-7,557.70%	🇺🇸 USA
Thermo Fisher Scientific TMO	34.4	-3,077.71%	🇺🇸 USA
Esperion Therapeutics ESPR	-0.8227	-28.72%	🇺🇸 USA
Illumina ILMN	-5.07	339.45%	🇺🇸 USA
Ligand Pharmaceuticals LGND	72.8	-6,405.30%	🇺🇸 USA
Aerie Pharmaceuticals AERI	-20.3	1,661.80%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.